243 related articles for article (PubMed ID: 27779808)
1. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.
Imura Y; Nakai T; Yamada S; Outani H; Takenaka S; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
Cancer Sci; 2016 Dec; 107(12):1867-1876. PubMed ID: 27779808
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
4. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
5. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma.
Motoi T; Ishida T; Kuroda M; Horiuchi H; Oka T; Matsumoto K; Nakamura T; Machinami R
Pathol Int; 1998 Oct; 48(10):769-75. PubMed ID: 9788260
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.
Fleuren EDG; Vlenterie M; van der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; van Erp A; van Houdt L; Cebeci SAS; van de Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ
Cancer Res; 2017 Aug; 77(16):4279-4292. PubMed ID: 28634201
[TBL] [Abstract][Full Text] [Related]
8. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma.
Oda Y; Sakamoto A; Saito T; Kinukawa N; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2000 Feb; 31(2):185-92. PubMed ID: 10685632
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma.
Kuhnen C; Tolnay E; Steinau HU; Voss B; Müller KM
Virchows Arch; 1998 Apr; 432(4):337-42. PubMed ID: 9565343
[TBL] [Abstract][Full Text] [Related]
11. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
12. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
13. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor.
Nishio J; Iwasaki H; Ishiguro M; Ohjimi Y; Fujita C; Isayama T; Naito M; Oda Y; Kaneko Y; Kikuchi M
Int J Oncol; 2002 Jul; 21(1):17-23. PubMed ID: 12063544
[TBL] [Abstract][Full Text] [Related]
15. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
17. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
18. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
19. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
20. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
